GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 110 participants.

Also called NCT05356104

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 110 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05356104
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China, Hong Kong SAR China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05356104. Randomized; single masking; primary purpose treatment. Start 2022-05-25 (actual); primary completion 2027-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
Acronym
GAPP-SVD
Condition
Cerebral Small Vessel Disease
Intervention (Drug)
GLP-1 receptor agonist
Lead sponsor
Chinese University of Hong Kong (class: other)
Collaborator
First Affiliated Hospital of Wenzhou Medical University (class: other)

Record details

Record id
cardio:ct-nct05356104
Content hash
573eb6e3a144878646d8841fa6a288a1d8030b13b4166e5732b82f07794f88b2